The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times FDA takes first step in possible reversal of ban on some peptides The Washington Post BPC 157 Capsules Vios Compounding The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide